SM
MDGL icon

Sabby Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sabby Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,500
Closed -$232K – 136
2018
Q3 		$321K Buy
+1,500
New +$376K 0.04% 85
2015
Q2 		– Sell
-11,400
Closed -$794K – 346
2015
Q1 		$794K Buy
+11,400
New +$978K 0.03% 209
2013
Q4 		– Sell
-7,170
Closed -$1.58M – 235
2013
Q3 		$1.58M Buy
7,170
+991
+16% +$211K 0.1% 101
2013
Q2 		$1.08M Buy
+6,179
New +$1.61M 0.07% 115

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Sabby Management's MDGL Position: Q4 2018 in Review

Sabby Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2018, closing a stake of 1,500 shares — an estimated $232K sold.

Sabby Management first reported a position in MDGL in Q2 2013 and held it in 4 quarters. The position peaked at $1.58M in Q3 2013. 136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

  • Sabby Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Sabby Management sold 1,500 Madrigal Pharmaceuticals shares in Q4 2018, an estimated $232K.
  • Sabby Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Sabby Management's Madrigal Pharmaceuticals position peaked at $1.58M in Q3 2013.
  • 136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.